The Animal Vaccines Market Size was valued at USD 10.1 billion in 2022 and is projected to grow from USD 10.7 Billion in 2023 to USD 15.3 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.6% during the forecast period (2023 - 2032). Increasing outbreaks of cattle disease and rising awareness of preventing the transmission of infectious diseases are some of the market drivers for Animal Vaccines.
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
The timely identification and proactive intervention are crucial for the management of developing illnesses. The rapidity with which the diagnosis and identification of SARS-CoV occurred exemplifies the role of technology in facilitating our response and mitigation endeavors. The increase of the market may be attributed to several causes, including the rise in livestock populations, the implementation of supporting government initiatives, and the occurrence of illnesses in cattle and sheep. The increasing demand for animal products can be attributed to several reasons, such as population expansion and shifts in dietary preferences due to evolving lifestyles.Â
In order to minimize detection and response durations, it is imperative to employ these expeditious diagnostic procedures in practical settings, so facilitating comprehension of the etiology of the ailment, thereby enabling the development of vaccinations and medications. This is especially necessary for illnesses that have the potential to cause damage to domestic cattle. Hence, the increasing need for disease prevention serves as a significant driver for the compound annual growth rate (CAGR) of the Animal Vaccines market.
Various animal species, such as cows, buffalo, sheep, and goats, offer a diverse range of goods, including meat, milk, and raw materials such as wool. Therefore, it is imperative to administer vaccinations to these bovines, since their potential infection might have detrimental consequences on the quality of those goods. Hence, governments in several nations are providing support and fostering knowledge concerning the immunization of livestock as a preventive measure against infection. The increasing number of government initiatives is expected to contribute to the expansion of the industry in the foreseeable future.Â
September 2023:To further advance the development and optimization of the Company's lipid nano particle (LNP)-based veterinary vaccine platform for veterinary diseases, Applied DNA Sciences, Inc., a leader in polymerase chain reaction (PCR)-based technologies, and the Cornell University College of Veterinary Medicine (CUCVM) have signed a sponsored research agreement in September 2023. When it comes to veterinary medical education, animal medicine, and biomedical research, CUCVM is among the best institutions in the world. The research aims to speed up the creation of a one-of-a-kind vaccination platform for infectious disease prevention in animals that is both adaptable and economical.
Animals play an important role in human societies because they provide us with food, transportation, raw materials, energy, and leisure. Additionally, in societies nowadays, pets like dogs, cats, and horses are frequently regarded as "companions." It has been demonstrated that they are valuable in long-term care facilities. Along with these significant contributions, there is growing concern over diseases humans can contract from animals (e.g., zoonoses). It has been shown that zoonoses are overrepresented among emerging human diseases and account for 61% of all human pathogens. Early detection and intervention are necessary for the control of emerging diseases. The astounding speed with which the SARS-CoV was diagnosed and identified shows how technology has aided our response and mitigation efforts. To reduce detection and reaction times, these rapid diagnostic tests must be used in the field, which also helps in understanding the cause of the disease so that vaccines and medicines can be manufactured. This is particularly required for diseases that can harm domestic livestock. Thus, the growing need for the prevention of these diseases is one of the key factors driving the market CAGR for Animal Vaccines.
Figure 1: Pet population in major countries
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
American Veterinary Medical Association, In recent years, the number of dogs and cats, as well as the proportion of households with either a dog or a cat, have all increased, but the number of pets per household has decreased. In 2020, 40% of cats and 38% of dogs came from animal shelters, making them a significant source of new pet acquisition. 45% of households had dogs in 2020, up from 38% at the end of 2016. Between 83.7 million and 88.9 million dogs were considered pets in 2017, an increase of 9% to 16% from year-end 2016. According to HealthforAnimals, more than half of people live with pets. Families own more than 500 million dogs and cats in the U.S., EU, and China alone. Moreover, according to American Pet Products Association's 2021-2022 National Pet Owners Survey, in 2021, the total U.S. Pet Industry Expenditures were USD 123.6 billion. Thus, the growing number of pets and rising expenditure for pet caring is anticipated to accelerate the Animal Vaccines market revenue globally.
The growing cattle population also fuels the need for cattle vaccines to prevent this Animal from being infected by various animal diseases. According to the National Agricultural Statistics Service (NASS) semiannual Cattle report, the total number of cattle and calves by January 2022 was estimated at 91.90 million head—2%, or nearly 1.88 million less than the previous year. The inventory of cattle and calves was 94.805 million head in 2019, but it has decreased over the last three years to its current level. Animals such as cows, buffalo, sheep, and goats provide various products including meat, milk, and raw materials such as wool. Thus, it is necessary to vaccinate these cattle as if they are infected, it can affect the quality of these products. Thus, the government in various countries is supporting and creating awareness regarding the vaccination of cattle to prevent them from being infected. Such growing government initiatives are also aiding market growth in the coming years..
The Market segments of Animal Vaccines, based on type, includes Porcine Vaccines, poultry vaccines, livestock vaccines, companion animal vaccines, and aquaculture vaccines. The livestock vaccines segment held the majority share in 2022 in the Animal Vaccines Market data. Increasing livestock populations, supportive government programs, and the emergence of diseases in cattle and sheep are some of the factors contributing to the market's expansion. The demand for livestock products is also rising as a result of a number of factors, including population growth and variations in food preferences brought on by changing lifestyles. The companion animal vaccines segment is expected to be the faster-growing segment during the forecast period, 2023-2032. The growing companion animal population and rising expenditure on pet care, such as veterinary care, are key factors boosting the market growth.
June 2022: The nation's first domestic COVID-19 vaccine for animals, Anocovax, was unveiled y Agriculture Minister Narendra Singh Tomar. It was created by the ICAR-National Research Center on Equines in Haryana (NRC). Anocovax is an animal vaccines against SARS-CoV-2 Delta (COVID-19).
Figure 2: Animal Vaccines Market, by Technology, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
The Animal Vaccines Market segmentation, based on technology, includes live attenuated vaccines, inactivated vaccines, toxoid vaccines, recombinant vaccines, and others. The live attenuated vaccines segment dominated the market growth for Animal Vaccines in 2022 and is projected to be the faster-growing segment during the forecast period, 2022-2030. Companies in the market are launching live-attenuated vaccines to prevent various animal diseases, such as the Zika virus and SARS-COVID-19. The growing R&D activities, rising number of pipeline products, and growing government initiatives for creating vaccine awareness are among the key factors driving the segmental growth.
March 2023:A new facility at the UK's Pirbright Institute will prioritize the rapid development of animal vaccines to combat emerging and urgent infectious diseases that threaten global food security and international trade, as well as pose a serious threat to global human health from their potential to spread as pandemics, starting in March 2023. A collaborative effort between the Biotechnology and Biological Sciences Research Council (BBSRC), the Foreign, Commonwealth, and Development Office (FCDO), and the Bill & Melinda Gates Foundation, the Centre for Veterinary Vaccine Innovation and Manufacturing (CVIM) seeks to fill the knowledge gaps between research and expertise in process development and manufacturing.Â
By region, the study provides market insights for Animal Vaccines into North America, Europe, Asia-Pacific, and the Rest of the World. The North America Animal Vaccines market accounted for USD 1.8 billion in 2022 with a share of around 45.80% and is expected to exhibit a significant CAGR growth during the study period. The high incidence of livestock and zoonotic illnesses causing widespread animal fatalities contributes to this significant share. Additionally, there are numerous reputable pharmaceutical companies that continually work to get their vaccines widely commercialized. The rise of the regional market is also aided by the rising prevalence of canine diseases, driving vaccination adoption.
Further, the significant countries studied in the market report for Animal Vaccines are: The U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil..
Figure 3: ANIMAL VACCINES MARKET SHARE BY REGION 2022 (%)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
Europe Animal Vaccines market accounts for the second-largest market share. The rising frequency of respiratory illnesses in animals and increased research efforts by industry players to provide better vaccines are anticipated to drive market expansion. Moreover, the UK market of Animal Vaccines held the largest market share, and the Germany market of Animal Vaccines was the fastest-growing market in the region.
Asia Pacific Animal Vaccines Market is expected to grow at the fastest CAGR from 2023 to 2032. The region's market growth is likely to be boosted by several important key factors, including the predicted increase in the cattle population and government initiatives, particularly in developing nations. India market of Animal Vaccines held the largest market share in the region owing to the growing cattle population. According to the National Dairy Development Board, India's cow population increased from 190.9 million in 2012 to 192.5 million in 2019. Further, the China market of Animal Vaccines is anticipated to grow at a significant CAGR during the projected period.
Animal Vaccines Key Market Players & Competitive Insights
Major market players are investing a lot of money in R&D to expand their product portfolios, which will spur further expansion of the market of Animal Vaccines. Players in the market are initiatives with key market developments such as introducing new products, acquisitions, contractual agreements, increased investments, and collaboration with other players. Competitors in the Animal Vaccines industry must constantly focus on developing vaccines to help prevent outbreaks.
Manufacturers in the global Animal Vaccines industry are constantly conducting clinical trials to study their vaccines for animals. In recent years, the Animal Vaccines industry has provided vaccines for diseases such as E.coli infection, salmonella infection, rabies, Zika virus, and FMD, among others. The Animal Vaccines market major player such as Boehringer Ingelheim International GmbH (Germany), Zoetis Inc. (US), Ceva Santé Animale (France), Merck & Co. Inc. (US), Elanco Animal Health Incorporated (US), Virbac (France), Phibro Animal Health Corporation (US), Hipra (Spain), Biogénesis Bagó S.A.(Argentina), and Neogen Corporation (US) are constantly working on raising investments and funds to support their research activities.
Ceva Santé Animale is a company dedicated to developing, manufacturing, and supplying vaccines, pharmaceuticals, and other animal health products, as well as the tools, expertise, technical support, and services necessary to ensure their effective use. In June 2022, Ceva Santé Animale (Ceva) acquired Artemis Technologies, Inc., a Canadian oral rabies vaccine manufacturer.
Merck Animal Health provides technologies and veterinary services that help advance animal healthcare. In September 2022, Merck Animal Health, in honor of World Rabies Day, announced that it had donated more than five million doses of its NOBIVAC rabies vaccine In order to help eradicate canine-mediated rabies. Through its Afya Program, Merck Animal Health provided the vaccines to significant partners like Mission Rabies and Rabies Free Africa, which administer the shot to dogs through widespread vaccination campaigns in regions of the world where rabies is still an endemic problem.
Key Companies in the market of Animal Vaccines iinclude
Animal Vaccines Industry Developments
May 2022:Â Zoetis launched Poulvac Procerta HVT-IBD for infectious bursal disease (IBD). It is a recombinant vector vaccine that provides early protection against infectious bursal disease (IBD).
September 2020:Â Hester Biosciences Limited, a leader in animal healthcare, announced that it would create a Brucella vaccine that provides improved safety, immunogenicity, and lifelong immunity with a single shot in calf-hood. The company also announced that a contract had been signed with the Indian Council of Agriculture Research (ICAR) and Indian Veterinary Research Institute (IVRI) to purchase the locally developed technology for the Brucella Abortus S19 Delta Per vaccine.
North America
Europe
Asia-Pacific
Rest of the World
Middle East
Africa
Latin America
| Report Attribute/Metric | Details |
| Market Size 2022 | USD 10.1 billion |
| Market Size 2023 | USD 10.7 billion |
| Market Size 2032 | USD 15.3 billion |
| Compound Annual Growth Rate (CAGR) | Â 7.6% (2023-2032) |
| Base Year | 2022 |
| Market Forecast Period | 2023-2032 |
| Historical Data | 2018 - 2021 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Technology and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and Rest of the World |
| Countries Covered | The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Boehringer Ingelheim International GmbH (Germany), Zoetis Inc. (US), Ceva Santé Animale (France), Merck & Co. Inc. (US), Elanco Animal Health Incorporated (US), Virbac (France), Phibro Animal Health Corporation (US), Hipra (Spain), Biogénesis Bagó S.A.(Argentina), and Neogen Corporation (US) |
| Key Market Opportunities | Growing incidence of cattle dieseases |
| Key Market Dynamics | Rising adoption of companion animals Growing veterinary expenditure |
Animal Vaccines Market Highlights:
Frequently Asked Questions (FAQ) :
The Animal Vaccines Market size was valued at USD 10.1 Billion in 2022.
The global market for Animal Vaccines is projected to grow at a CAGR of 7.6% during the forecast period, 2023-2032.
North America had the largest share of the global market for Animal Vaccines.
The key players in the market for Animal Vaccines are Boehringer Ingelheim International GmbH (Germany), Zoetis Inc. (US), Ceva Santé Animale (France), Merck & Co. Inc. (US), Elanco Animal Health Incorporated (US), Virbac (France), Phibro Animal Health Corporation (US), Hipra (Spain), Biogénesis Bagó S.A.(Argentina), and Neogen Corporation (US).
The Livestock Vaccines category dominated the Animal Vaccines market in 2022.
The live attenuated vaccines had the largest share of the Animal Vaccines Market.
Research Analyst Level I He is an extremely curious individual currently working in healthcare and medical devices domain. kinjoll is comfortably versed in data centric research backed by healthcare educational background. he leverages extensive data mining and analytics tools such as primary and secondary research, statistical analysis, machine learning, data modelling. his key role also involves technical sales support, client interaction and project management within the healthcare team. lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
